Abstract: Provided are Janus kinase 1 selective inhibitors of Formula 1 or Formula 2: wherein R1, R2, and X are as described herein. Pharmaceutical uses thereof, for example, for the treatment of a disease associated with a Janus kinase, are also provided.

Abstract: A novel substituted N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine and a use thereof as a Janus kinase (JAK) inhibitor are provided.

Abstract: A novel substituted N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine and a use thereof as a Janus kinase (JAK) inhibitor are provided.

Abstract: A method for preventing and treating thrombotic disorders in a subject in need thereof comprising, administering a pharmaceutical composition comprising an extract of Lindera obtusiloba as an active ingredient to the subject. A pharmaceutical composition and a health functional food for preventing and treating thrombotic disorders by improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient. The extract of Lindera obtusiloba of the present invention and a crude purified product thereof can be obtained through extraction using various solvents such as water, ethanol, methanol, butanol, etc. Since the extract and the crude purified product have not only excellent inhibitory effect on platelet aggregation induced by various aggregation inductions in vitro, but also excellent inhibitory effect on rapid thrombus formation in vivo, they can be useful for preventing and treating diseases caused by blood circulation disorders such as thromboembolism, etc.

Abstract: The present invention relates to a composition for treatment and prevention of cardiovascular diseases, containing an extract of Lindera obtusiloba. More particularly, the extract of Lindera obtusiloba strongly inhibits NAD(P)H oxidases, which are the main cause of vascular diseases, and at the same time, regulates contraction and relaxation of vascular smooth muscles to manifest a potent vasorelaxant effect, thereby improving the blood pressure regulation and vascular endothelial dysfunction. Therefore, a composition containing this as an active ingredient can be usefully utilized as a pharmaceutical product or health functional food product for the prevention and treatment of cardiovascular diseases.

Abstract: Provided is a composition for improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient, and more specifically, to a pharmaceutical composition and a health functional food for preventing and treating thrombotic disorders by improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient. The extract of Lindera obtusiloba of the present invention and a crude purified product thereof can be obtained through extraction using various solvents such as water, ethanol, methanol, butanol, etc. Since the extract and the crude purified product have not only excellent inhibitory effect on platelet aggregation induced by various aggregation inductions in vitro, but also excellent inhibitory effect on rapid thrombus formation in vivo, they can be useful for preventing and treating diseases caused by blood circulation disorders such as thromboembolism, etc.

Abstract: The present invention relates to a composition for treatment and prevention of cardiovascular diseases, containing an extract of Lindera obtusiloba. More particularly, the extract of Lindera obtusiloba strongly inhibits NAD(P)H oxidases, which are the main cause of vascular diseases, and at the same time, regulates contraction and relaxation of vascular smooth muscles to manifest a potent vasorelaxant effect, thereby improving the blood pressure regulation and vascular endothelial dysfunction. Therefore, a composition containing this as an active ingredient can be usefully utilized as a pharmaceutical product or health functional food product for the prevention and treatment of cardiovascular diseases.